Business
Cerus Corporation Announces Record Results for Third Quarter 2025 and Raises Full Year 2025 Product Revenue Guidance
Third Quarter Total Revenue up 19% to $60.2 Million; Record Product Revenue of $52.7 Million, Up 15% Year-Over-Year Raising Full-Year 2025 Product Revenue
About this update from Cerus Corporation
[{"type":"text","content":"\nThird Quarter Total Revenue up 19% to $60.2 Million; Record Product Revenue of $52.7 Million, Up 15% Year-Over-Year\n\nRaising Full-Year 2025 Product Revenue Guidance Range to $202 Million - $204 Million\n\n CONCORD, Calif.--(BUSINESS WIRE)--\nCerus Corporation (Nasdaq: CERS) announced today financial results for the third quarter ended September 30, 2025, and provided a business update.\n\n“We continue to make great strides in improving the safety and availability of transfused blood components around the globe and the record quarterly product revenue results reflect that progress. Product revenue growth was driven by strong global commercial execution and growing awareness of the benefits conferred by our INTERCEPT Blood System. Furthermore, hospital demand for INTERCEPT fibrinogen complex or IFC in the U.S. continues to increase, bolstered by the many positive case studies from large academic hospitals that have implemented IFC in routine use,” said William “Obi” Greenman, Cerus’ president and chief executive officer.\n\nAdditional highlights include:\n\n\nThird-quarter 2025 total revenue comprised of (in millions, except percentages):\n\n\n\n\n\nThree Months Ended\n\n\n\n\n\n\n\n \n\n\n\nNine Months Ended\n\n\n\n\n\n\n\n\n\n\nSeptember 30,\n\n\n\n \n\n\n\nChange\n\n\n\n \n\n\n\nSeptember 30,\n\n\n\n \n\n\n\nChange\n\n\n\n\n\n\n2025\n\n\n\n \n\n\n\n2024\n\n\n\n \n\n\n\n$\n\n\n\n \n\n\n\n%\n\n\n\n \n\n\n\n2025\n\n\n\n \n\n\n\n2024\n\n\n\n \n\n\n\n$\n\n\n\n \n\n\n\n%\n\n\n\n\n\nProduct Revenue\n\n\n\n$52.7\n\n\n\n\n$46.0\n\n\n\n\n$6.7\n\n\n\n\n15%\n\n\n\n\n$148.4\n\n\n\n\n$129.5\n\n\n\n\n$18.9\n\n\n\n\n15%\n\n\n\n\n\nGovernment Contract Revenue\n\n\n\n7.5\n\n\n\n\n4.6\n\n\n\n\n2.9\n\n\n\n\n63%\n\n\n\n\n20.8\n\n\n\n\n15.1\n\n\n\n\n5.7\n\n\n\n\n38%\n\n\n\n\n\nTotal Revenue\n\n\n\n$60.2\n\n\n\n\n$50.7\n\n\n\n\n$9.6\n\n\n\n\n19%\n\n\n\n\n$169.2\n\n\n\n\n$144.6\n\n\n\n\n$24.6\n\n\n\n\n17%\n\n\n\n\n\nNumbers may not sum due to rounding. Percentages calculated from unrounded figures.\n\n\n\n\n\nHospital demand for IFC continues to increase with third quarter volumes (equivalent to FC15* therapeutic units) up approximately 110% compared to the prior year period. Q3 U.S. IFC sales totaled $3.9 million, up from $2.3 million during the prior year period.\n\n\nCompleted enrollment in the U.S. RedeS trial, the second pivotal U.S. Phase 3 ...